CD79A and Arthritis: It is interesting to note that while in patients with established RA, the proportion of patients with anti-AcetVim IgG is around 35% and significantly higher compared to patients with persistent non-RA arthritis, the prevalence anti-AcetVim IgA is absolutely overlapping in these two groups and is again about 35%.